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Abstract
High grade gliomas (HGG) are one of the leading causes of cancer-related deaths in children, and there is increasing
evidence that pediatric HGG may harbor distinct molecular characteristics compared to adult tumors. We have sought to
clarify the role of microsatellite instability (MSI) in pediatric versus adult HGG. MSI status was determined in 144 patients (71
pediatric and 73 adults) using a well established panel of five quasimonomorphic mononucleotide repeat markers.
Expression of MLH1, MSH2, MSH6 and PMS2 was determined by immunohistochemistry, MLH1 was assessed for mutations
by direct sequencing and promoter methylation using MS-PCR. DNA copy number profiles were derived using array CGH,
and mutations in eighteen MSI target genes studied by multiplex PCR and genotyping. MSI was found in 14/71 (19.7%)
pediatric cases, significantly more than observed in adults (5/73, 6.8%; p = 0.02, Chi-square test). MLH1 expression was
downregulated in 10/13 cases, however no mutations or promoter methylation were found. MSH6 was absent in one
pediatric MSI-High tumor, consistent with an inherited mismatch repair deficiency associated with germline MSH6 mutation.
MSI was classed as Type A, and associated with a remarkably stable genomic profile. Of the eighteen classic MSI target
genes, we identified mutations only in MSH6 and DNAPKcs and described a polymorphism in MRE11 without apparent
functional consequences in DNA double strand break detection and repair. This study thus provides evidence for a potential
novel molecular pathway in a proportion of gliomas associated with the presence of MSI.
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Introduction
Pediatric gliomas comprise a diverse group of lesions which
account for more than half of all childhood CNS tumors. In
contrast to adults, where WHO grade IV glioblastomas predom-
inate, in children the most common form are WHO grade I
pilocytic astrocytomas [1]. Despite the rarity of high grade gliomas
(HGG) in children, they are one of the leading causes of cancer-
related deaths in this age group, with a current two year survival
rate of 10–15% [2]. Although histologically similar to those which
arise in adults, HGG in children may have distinct clinical
features, including anatomical site of presentation [2] and response
to chemotherapy [3].
New evidence also demonstrates that pediatric HGG harbor
distinct genetic characteristics compared to adult tumors. Recent
large-scale genomic studies on adult glioblastomas defined the key
genetic aberrations, and proposed the ‘core signaling pathways’
driving gliomagenesis [4,5]. Similar studies on pediatric tumors
demonstrated fewer genomic events targeting these pathways, and
identified alterations in PDGF-driven signaling to be prevalent in
the majority of pediatric tumors, in contrast to adults, where
EGFR is the predominant target [6]. The finding of a significant
proportion of childhood HGG to harbor few chromosomal
imbalances is one key difference to those seen in adults [6], and
raises questions regarding the underlying biological basis for these
highly aggressive tumors.
The presence of microsatellite instability (MSI), is another feature
that has been described to be more frequent in pediatric than in
adult brain tumors [7,8,9,10,11]. Nevertheless, the results are
conflicting, with reported frequencies in pediatric gliomas varying
between 0–44%, possibly due to different sensitivities of the methods
used to detect MSI status [12,13,14,15,7,8,9,10,11,16,17]. MSI was
first described and is better characterized in hereditary non-polyposis
colorectal cancer (HNPCC, Lynch syndrome) [18], where it is
thought to arise due to germline mutations in mismatch repair
(MMR) genes, mainly in MLH1, MSH2, MSH6 and PMS2 [19].
Germline mutations in these genes have also been described in
Turcot’s syndrome, which predispose to gliomas [1].
Both in familial and sporadic colorectal cancer (CRC), the
presence of MSI is associated with mutations in genes harboring
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microsatellites in their coding or regulatory regions. Genes
involved in DNA repair, cell growth inhibition and apoptosis are
targeted, although the frequency varies between cancers [20], and
an extensive analysis has not been previously performed in MSI
gliomas. We have sought to clarify the role of MSI in pediatric
versus adult HGG, and report a higher prevalence of MSI in
childhood cases. We have further investigated the role of MMR
system proteins, genomic instability and 18 known target genes in
pediatric MSI HGG.
Methods
Cases and DNA isolation
Formalin-fixed paraffin-embedded (FFPE) HGG samples from
71 children and young people (,23 years) and 73 adults (32–79
years) were obtained after approval by Local and Multicenter
Ethical Review Committees from King’s College Hospital and St
George’s Hospital, UK and Federal University of Sa˜o Paulo,
Brazil (Table S1). The pediatric cases were obtained from all three
Health Institutions. All the samples enrolled in the present study
were unlinked and unidentified from their donors. Due the
retrospective nature of the study, no written informed consent
from patients was obtained, with the exception of the UK samples
obtained after 2006, where all patients signed a written informed
consent, following the UK Human Tissue Act approved in that
year. The Local Ethical Review Committees of Federal University
of Sa˜o Paulo, Brazil waived the need for written informed consent.
The presence of tumor tissue in these samples and the tumor
histology was verified on a H&E-stained section independently by
three neuropathologists (SA-S, LRB, JNS). DNA was isolated
using the QIAamp DNAMini kit (Qiagen) according to the
manufacturer’s instructions.
MSI analysis
MSI was assessed using a multiplex PCR comprising five
quasimonomorphic mononucleotide repeat markers (NR27,
NR21, NR24, BAT25 and BAT26), as previously described
[21]. Products were separated using an ABI Prism 3100 genetic
analyzer (Applied Biosystems) and results analyzed with GeneScan
Analysis software, version 3.7 (Applied Biosystems). In the absence
of matched normal DNA, MSI was defined as MSI-High (MSI-H,
instability at three or more markers) MSI-Low (MSI-L, instability
at one or two markers) or microsatellite stable (MSS, absence of
instability) [22]. The quasimonomorphic variation range (QMVR)
of each marker, previously described [23] was established in our
analysis using a series of DNA samples from 30 controls which
were randomly selected from cancer-free blood donors at the ICR,
UK and Sa˜o Marcos Hospital, Portugal.
Mutation analysis of MSI-targeted genes
Selected genes containing repeat sequences, previously de-
scribed as frequent targets for MSI in other cancers [24,25,26],
were chosen for mutation screening (primers available upon
request): ATM (poly(T)13), ATR (poly(A)10), AXIN2 (poly(G)7;
poly(C)5; poly(C)6), BAX (poly(G)8), BLM (poly(A)9), BRCA1
(poly(A)8), BRCA2 (poly(A)8), DNAPKcs (poly(A)10), MBD4 (poly(-
A)10), MRE11 (poly(T)11), MSH3 (poly(A)8), MSH6 (poly(C)8),
PTEN exon 7 (poly(A)6), PTEN exon 8 (poly(A)6), RAD50
(poly(A)9), TCF4 (poly(A)9), TGFbRII (poly(A)10), WISP3 (poly(-
A)9) and XRCC2 (poly(T)8). PCR and genotype analysis were
performed as previously described [21], except AXIN2, which was
directly sequenced after PCR [25]. Samples presenting abnormal
profiles were direct sequenced to confirm the presence of
frameshift mutations.
Immunohistochemistry
Immunohistochemistry for MLH1, MSH2, MSH6, PMS2 and
MRE11 was performed using the Vectastain ABC system (Vector),
according to the manufacturer’s instructions. Antigen retrieval was
achieved in boiling waterbath in Tris-EDTA pH 9.0 for 20 min
and primary antibodies MLH1 (G168-15, 1:25, BD Biosciences),
MSH2 (FE11, 1:150, Calbiochem), MSH6 (44, 1:100, BD
Biosciences), PMS2 (A16-4, 1:200, BD Biosciences) and MRE11
(12D7, 1:500, Abcam) were incubated overnight at 4uC.
For DNAPKcs staining, the Ultravision Plus Detection System
(LabVision) was used according to the manufacturer’s instructions.
Antigen retrieval was performed with microwave treatment in
citrate buffer pH 6.0 for 15 min and primary antibody (Ab-4
cocktail, 1:100, NeoMarkers) incubated 2 h at RT.
Microscopic analysis was done by a blinded pathologist (S. P.).
Sections without staining in the tumor cells were considered to
have a lost expression (2). Samples without nuclear staining but
positivity in the cytoplasm or with ,5% tumor cells with nuclear
staining were considered with diminished expression (+). Samples
with the scores ++ (5–50% nuclear staining in tumor cells) or +++
(.50% nuclear staining in tumor cells) were considered positive.
Mutation analysis and methylation-specific (MS) - PCR of
MLH1
Mutation analysis of MLH1, exons 1 to 19, was performed by
PCR, using primers previously described [27], followed by direct
sequencing.
For MLH1 promoter methylation detection, DNA was treated
with sodium bisulphite using the Epitect kit (Qiagen) according to
the manufacturer’s instructions. MS-PCR was performed using
primers previously described [28].
Cell culture and ionizing irradiation
The cell lines Daudi, Raji and Jurkat were kindly provided by Dr
Sue Colman/Prof Mel Greaves (ICR, UK). Cells were grown in
suspension in RPMI 1640 medium supplemented with 10% fetal
bovine serum at 37uC in 5% CO2. Cells were seeded in 35 mm Petri
dishes and treated with 1.5 Gy ionizing irradiation (IR) using an X-
ray source irradiator (HS-MP1, AGO) operating at 250 kv and
10 mA. Cells were allowed to recover for 1 h, 4 h or 24 h and then
processed for immunofluorescence staining or western-blot analysis.
Immunofluorescence
Cells were spun at 200 rpm for 5 min on a Shandon Cytospin 3
centrifuge (Thermo Fisher Scientific), fixed according to a
modified Strecks pre-extraction protocol, permeabilized and
blocked, as described [29]. Primary antibodies directed against
MRE11 (Sheep polyclonal, 1:500, previously described [30]),
53BP1 (NB100-304, rabbit polyclonal, 1:100, Novus Biologicals)
and phospho-Histone H2A.X (Ser139) (JBW301, mouse mono-
clonal, 1:2000, Millipore) were applied overnight at 4uC and
secondary antibodies, Alexa Fluor 594 donkey anti-goat IgG,
Alexa Fluor 488 donkey anti-rabbit IgG and Alexa Fluor 488
donkey anti-mouse IgG (Invitrogen) 1 h at RT. Cell nuclei were
stained with DAPI (Invitrogen). Images were taken using a Zeiss
Axioplan 2 microscope and Smartcapture 2 software (Digital
Scientific).
Western blot analysis
Protein extracts were separated in a 3–8% Tris-Acetate gel
(Invitrogen) and transferred to PVDF membranes (GE Health-
care). Immunodetection was performed using antibodies directed
against phospho-ATM (Ser1981) (10H11.E12, 1:500, Cell Signal-
MSI in Pediatric High Grade Glioma
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ing), ATM (MAT3-4G10/8, 1:1000, Sigma-Aldrich), and MRE11
(12D7, 3 mg/mL, Abcam).
Quantitative Real-Time PCR
cDNA was prepared from 1 mg of RNA by random primed
reverse transcription using Superscript III (Invitrogen). qRT-PCR
was performed using SYBR green master mix (Applied Biosys-
tems) on an ABI 7900HT loaded with the SDS2.1 software.
Primers used were as follows: total MRE11 mRNA (exons 2–4),
CCAGGGGTTCTTGGAGAAG (forward) and TTTCCTTGA-
GGGCTTATTTTCA (reverse); MRE11 distinguishing the aber-
rant and wild-type transcript (exons 2–6) included the same
forward primer and CCAGCACAACTTAAAATGTC (reverse);
GAPDH, GCCACCCAGAAGACTGTGGATGGC (forward)
and CATGATGGCCATGAGGTCCACCAC (reverse). GAPDH
mRNA levels were measured as an internal control. The number
of amplification cycles to half maximal saturation of the PCR
product was determined by measuring the integration of the
fluorescent dye into the PCR products. The ratio of the level of
MRE11 expression relative to the GAPDH control was calculated.
Samples were analyzed on a 4% agarose gel loaded after
saturation of the PCR reaction.
Statistical Analysis
All statistical tests were done in SPSSv16.0 (SPSS Inc.). Correlations between
categorical values were done using the two-tailed Chi-square and Fisher’s exact
tests. A p value of,0.05 was considered significant.
Results
MSI is more common in pediatric HGG than in adults
MSI analysis was performed in 144 HGG, 71 pediatric and 73
adults, using a pentaplex PCR of quasimonomorphic markers as
recommended by the revised Bethesda guidelines [18]. A total of
19 samples (13.2%) presented instability, 1 MSI-H (,1%) and 18
MSI-L (12.5%) cases, with the remaining 125 tumors stable
(86.8%). The MSI-H case, RMH2452, was a three year old girl
with glioblastoma, presenting instability at four markers (NR27,
NR21, BAT25 and BAT26) (Figure 1). Overall, there were 14/71
(19.7%) MSI-positive pediatric cases, significantly more than
observed in adults (5/73, 6.8%; p= 0.02, Chi-square test). The
pediatric MSI cases comprised 11 glioblastomas, two anaplastic
astrocytomas and one anaplastic oligodendroglioma, with an age
range of between 4 months and 20 years. The adult MSI-L cases
were glioblastomas of ages 62–75 years (Table 1). Individual
microsatellite data for each case is provided in full in Table S1.
Inactivation of mismatch repair proteins in familial and
sporadic MSI pediatric HGG
Aiming to determine the underlying nature of the MSI observed
we sought to investigate whether key components of the MMR
system were intact, screening the MSI-positive samples for
expression of MLH1, MSH2, MSH6 and PMS2 by immunohis-
tochemistry (Table 1, Figure S1). 10/13 (76.9%) pediatric samples
with MSI showed an absent or diminished expression of MLH1 in
the tumor cells, often in concert with reduced MSH2 (4/10, 40%)
or PMS2 expression (4/10, 40%). There was, however, no
evidence of mutation (assessed by direct sequencing) or hyper-
methylation (by MS-PCR) of MLH1 in these cases. Due to the
FFPE nature of the samples, it was not possible to screen for
MLH1 mutations and promoter methylation in all MSI samples
(Table 1). Moreover, on samples screened for MLH1 mutations,
the rate of successful exons sequenced ranged from 58% (11/19
exons) to 100% (19/19 exons), according sample DNA quality. In
contrast to pediatric, the four adult MSI-L cases presented positive
immunoreactivity for MMR proteins.
A single case was negative only for MSH6. This patient
(RMH2452, MSI-H) presented multiple cafe´-au-lait spots in the
absence of other clinical features of neurofibromatosis-1 (NF1).
There was no family history of NF1, although the maternal great
grandmother had endometrial cancer in her early forties. Although
constitutional DNA was not available for testing, this patient’s
clinical history is consistent with an inherited MMR deficiency such
as Turcot’s syndrome, associated with germline MSH6 mutation.
MSI-positive pediatric HGG have distinct genomic
profiles and differential target genes compared with
other tumor types
As the presence of MSI reflects a nucleotide-level form of genetic
instability, work in CRC suggests that large scale chromosomal
instability is reduced or absent in MSI-positive cases [31,32]. In
order to determine whether this may also be true for pediatric
HGG, we examined copy number profiles on 9/14 MSI-positive
cases for which sufficient quantity and quality of DNA was
available, and compared this to a similarly profiled cohort of 26
pediatric MSS cases (Array Express accession number E-TABM-
857) [33]. A total of four MSI-positive cases harbored a ‘flat’ or
‘stable’ profile, with minimal or no copy number alterations
detectable on the 32K tiling-path BAC array platform used
(Figure 2, Table 2). This is a pattern of genomic stability present
in approximately 20% of pediatric HGG, but almost entirely absent
from similar adult tumors [6,34]. Four MSI-L cases harbored a
small number of whole chromosome arm gains or losses, and fell
into the ‘aneuploid’ category of genomic profile. There was a single,
MSI-L, case (RMH3954) that had a highly rearranged genome,
with 19 distinct alterations. No MSI-positive cases contained any
high-level amplifications or homozygous deletions. Overall there
were less copy number changes in MSI (mean 5.78, range 0–19)
than MSS cases (mean 8.35, range 0–25), although there was no
statistical difference in the groups (p= 0.37, t test), reflecting the
highly rearranged MSI-L case, and the presence of 4/26 (15.4%)
genomically stable cases by array CGH that were also MSS.
The presence of MSI confers an increased susceptibility for
acquiring mutations in various target genes containing single
nucleotide repeat sequences [20]. Selected CRC target genes
involved in apoptosis (BAX), tumor growth (TGFbRII), WNT
pathway (AXIN2, TCF4, WISP3), DNA repair (ATM, ATR, BLM,
BRCA1, BRCA2, DNAPKcs, MBD4, MRE11, MSH3, MSH6,
RAD50, XRCC2) and PI3-kinase signaling (PTEN) were analyzed
for mutations in MSI-positive HGG samples (Table 2).
The pediatric MSI-H sample was found to contain a homozygous
single base insertion in the poly(C)8 tract of MSH6 poly(C)9, a
frameshift which results in a truncated protein, confirmed in duplicate
by genotyping and direct sequencing (Figure 3A). Somatic mutations
on the poly(C)8 sequence of MSH6, are strongly associated with
initiatingMSH6 germline mutations [35], adding further evidence to
this patient having an inherited MMR deficiency syndrome.
A further MSI-L sample (RMH3969) presented a heterozygous
single base deletion in the poly(A)10 sequence on the exon 5 of
DNAPKcs (poly(A)9/10), however this mutation did not influence
protein expression, as observed by immunohistochemistry
(Figure 3B). Two other MSI-L cases, RMH2444 (Figure 3C)
and RMH3952 harbored a heterozygous single base insertion in
the poly(T)11 tract on the intron 4 of MRE11 (poly(T)11/12).
Immunohistochemistry again revealed positivity of the protein
(Figure 3C). This insertion was also observed in 1/5 adult cases
with MSI-L (RMH3248). No additional target gene mutations
were observed in our series (Table 2).
MSI in Pediatric High Grade Glioma
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MRE11 poly(T)11/12 is a previously unrecognized
polymorphism with no apparent functional consequence
in DNA double strand break detection and repair
As MRE11 represented a potentially unknown contributor to
the pathogenesis of HGG associated with MSI, we determined
whether the specific MRE11 poly(T)11/12 mutation affects the
normal function of the protein, a member of the MRE11-RAD50-
NBS1 (MRN) complex involved in DNA repair. As models we
used three leukemia/lymphoma cell lines (Figure 4A): Daudi,
MRE11 poly(T)11/12; Raji, MRE11 poly(T)11/11, wild type, and
DNA repair proficient; and Jurkat, MRE11 poly(T)10/11 known
to generate alternative splicing in exon 5 of MRE11 (Figure 4B)
and DNA repair deficient [26]. The presence of an aberrant
Figure 1. Microsatellite instability in pediatric HGG. Representative electropherogram traces for three MSI-positive pediatric HGG, presenting
sequence alterations in more than one quasimonomorphic marker. Case RMH2452 (MSI-H) presented alterations in NR27, NR21, BAT25 and BAT26;
RMH2458 (MSI-L) in NR21 and BAT25; and RMH4816 (MSI-L) in NR21 and NR24. Alterations in relation to a control trace are indicated with arrows.
doi:10.1371/journal.pone.0020588.g001
Table 1. Clinical characterization and MMR status of MSI cases.
Case Gender/Ag e WHO grade Diagnosis MSI status Immunohistochemistry
MLH1
mutation
screening
MLH1
methylation
status
MLH1 MSH2 MSH6 PMS2
Pediatric
2452 F/3 IV GBM MSI-H +++ +++ 2 ++ ND ND
2458 F/9 IV GBM MSI-L +++ +++ +++ ++ A A
4816 M/14 IV GBM MSI-L + ++ ++ ++ A NA
2444 M/19 IV GBM MSI-L 2/+ +++ +/++ ++ A A
2457 F/13 IV GBM MSI-L 2/+ ++ +++ 2/+ A A
2470 F/14 IV GBM MSI-L MC MC +/++ MC A A
3952 F/14 IV GBM MSI-L 2 NS NA ++ NA NA
3954 M/20 IV GBM MSI-L +++ ++ +++ +++ A A
3962 F/0.3 III AA MSI-L + 2 ++/+++ 2/+ A A
3967 F/8 III AO MSI-L + ++ ++/+++ NS A A
3969 F/14 IV GBM MSI-L MC MC +/++ MC A A
4820 M/16 IV GBM MSI-L + + + ++ NA NA
4823 M/15 IV GBM MSI-L + ++ 2 ++ NA NA
4839 M/16 IV GBM MSI-L NS ++ ++ ++ NA NA
Adult
3248 M/67 IV GBM MSI-L +++ +++ +++ ++ A NA
3283 M/63 IV GBM MSI-L +++ ++ ++/+++ +++ A NA
3415 M/70 IV GBM MSI-L NA NA NA NA NA NA
3416 F/75 IV GBM MSI-L 2 +++ +++ +++ A NA
3465 F/62 IV GBM MSI-L NS +++ +++ +++ A NA
Abbreviations: M, male; F, female; GBM, glioblastoma; AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; MSI-H, microsatellite instability-High; MSI-L,
microsatellite instability-Low; MC, mostly cytoplasmatic; NS, non-specific; A, absent; ND, not done; NA, not available.
doi:10.1371/journal.pone.0020588.t001
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transcript was detected by RT-PCR of exons 2 to 6with a
truncated product detected in Jurkat cells (Figure 4B). Levels of
total MRE11 mRNA were quantified by qRT-PCR amplification
of exons 2 to 4 which generates a single size product, for both wild-
type and the aberrant transcript. The ratios of the mRNA
expression levels of MRE11, relative to GAPDH, were similar
across all cell lines (Figure 4B) while protein levels were lower in
Jurkat (Figure 4B).
To assess the proficiency of MRE11-associated DNA repair in
MRE11 poly(T)11/12 Daudi, we monitored the repair response
following DNA damage induced by ionizing radiation. After
exposure to irradiation, auto-phosphorylation of ATM on serine-
1981 takes place in response to the formation of DNA double
stranded breaks (DSB) [36]. 1.5 Gy IR resulted in no ATM
phosphorylation in Jurkat, while Raji and Daudi, presented an
increase of ATM phosphorylation 1 h after IR followed by a slight
decrease in longer time points (Figure 4C). Another response to
ionizing radiation is the accumulation of DNA repair proteins
after exposure to irradiation that can be visualized in the form of
foci associated with recruitment of essential repair complexes to
the sites of DNA damage [37]. After 1.5 Gy IR, 53BP1 foci
formation after IR was proficient in all cell lines as these can form
even in the absence of a functional MRN complex (Figure 4D). In
Daudi and Raji, the co-localization between MRE11 and 53BP1
foci observed was suggestive of the formation of functional repair
complexes, in contrast to Jurkat, where no MRE11 foci were
present. Compared to Jurkat and Daudi, Raji non-irradiated cells
showed higher background levels of DNA damage as detected by
formation of cH2AX foci (Figure S2). In summary, these results
suggest that the MRE11 poly(T)11/12 mutation does not result in
a compromised DNA damage repair response in Daudi cells.
AlthoughMRE11 poly(T)11/12 alteration could not be found in
the dbSNP database, this specific base change was recently
identified in the germline of a Caucasian male [38]. We
subsequently screened a series of 72 control DNA samples, and
discovered MRE11 poly(T)11/12 to be present in 5/72 (6.9%)
healthy volunteers. Although this frequency is less than that
observed in the MSI-positive cases (3/19, 15.8%), the difference is
Figure 2. Genomic stability in MSI pediatric HGG. Array CGH genome plots are shown for two MSI-positive pediatric HGG, the MSI-H RMH2452
(A) and the MSI-L RMH2458 (B), demonstrating lack of large scale alterations detectable on the 32K BAC platform. Log2 ratios for each clone (y axis)
are plotted according to chromosomal location (x axis). The centromeres are represented by vertical lines.
doi:10.1371/journal.pone.0020588.g002
MSI in Pediatric High Grade Glioma
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20588
not statistically significant (p = 0.23, Chi-square test). Thus we
conclude that MRE11 poly(T)11/12 is a previously unrecognized
polymorphism with no functional consequences on the DNA
repair response.
Discussion
Published studies on MSI in HGG have produced contradictory
results. These differences have variously been attributed to the
number of samples studied, the heterogeneity and accuracy of
methods used to determine MSI status. We sought to address this
by carrying out a large study of HGG using the most robust and
sensitive screens available, and report a significantly elevated
frequency of MSI in pediatric (19.7%) versus adult (6.8%) tumors.
One of the key considerations in the assessment of MSI is in the
use of mononucleotides versus polynucleotides in the panel of
markers used. The quasimonomorphic nature of the mononucle-
otides we used makes these most suitable for MSI detection,
particularly when matching germline DNA is not available, and
display a higher sensitivity [23,39]. Many of the early studies used
polynucleotide markers only and found a frequency of MSI
ranging from of 0 to 37% in series of 7 to 56 gliomas from
pediatric or age not discriminated series [12,13,14,15]. Including
both mononucleotide and polynucleotides did little to improve
consistency, with contrasting results of 0 to 44% in small series of
pediatric gliomas [8,9,10] and 4% MSI reported in a recent study
using a larger series of 68 pediatric HGG [40]. Recent studies
using mononucleotides only were also contradictory. Alonso et al.
2001 [11] reported a frequency of 27% MSI in 45 pediatric HGG
using BAT25 and BAT26 as markers, while Eckert et al. 2007 [16]
found no evidence of MSI in 41 cases using CAT25, BAT25 and
BAT26. Vladimirova et al. 2007 [17] used the same panel of five
mononucleotides as in the present study, and yet found a reduced
frequency of 3.2% MSI in 126 pediatric HGG in comparison to
our 19.7%. One major difference between our studies that possibly
accounts for the diversity of frequencies is the use of 30 controls to
establish the QMVR in our work. As recently demonstrated, this
approach obviates the need for amplification of matched normal
DNA to determine instability in the tumor tissue, and provides the
most robust strategy to identify MSI tumors [39]. In addition, this
approach allowed us to assess smaller allelic shifts of the markers as
any variation outside the QMVR was considered as instability.
Although the data presented by previous studies do not allow for
re-analysis using this technique, we speculate that our increased
frequency of MSI may be related to enhanced detection sensitivity
[39]. In fact, a study in malignant gliomas, that used a panel of
markers similar to the one used in our work and performed a
QMVR using DNA from 7 normal controls, described the
presence of MSI-L in 15% (8/52) of cases, a frequency
comparable to our results (13%) [41].
Another important analytical difference may be found in the use
of an alternative classification of MSI which takes into account the
size of the allelic shifts in the markers, rather than the number of
markers with alterations. In this classification, samples presenting
small length change (#6 bp) are considered Type A, whilst those
presenting more drastic alterations are described as Type B MSI,
as reported for CRC [42]. Pediatric HGG with constitutive MMR
deficiency have been previously described as possessing Type A
MSI [43] and we also observed Type A MSI in our sporadic, and
likely syndromic cases. This is also consistent with our previous
observations in medulloblastoma [21], and appears to be a
consistent difference in MSI reported in CNS tumors compared
with the classic MSI positive epithelial tumors such as colorectal
and gastric carcinomas. The observation that brain tumors present
smaller changes in the MSI markers may represent a cause of the
inconsistency found on MSI frequencies reported in literature.
Having established that a proportion of our pediatric HGG
cases harbored MSI, we were keen to determine how this related
to other genomic abnormalities. Microsatellite and chromosomal
instability have been considered to be mutually exclusive [31], and
although recent reports have demonstrated that a minority of
tumors can present both MSI-H and chromosomal instability, the
frequency and degree of chromosomal alterations in colorectal and
gastric MSS cancers is much higher than in the MSI-H cases [32].
Pediatric HGG differ from those found in adults by comprising a
proportion of tumors with few or no detectable copy number
changes by microarray analysis [6]. The MSI-H sample in our
current cohort fell into that category. The MSI-L cases also had
relatively fewer alterations than the population as a whole, while
the presence of MSI and chromosomal instability were not
mutually exclusive. In particular, there were several cases with
‘stable’ genomes which did not present MSI, suggesting that
although this phenotype was associated with a proportion of cases
with no gross alterations, it was not a general explanation for this
key difference between the childhood and adult disease.
Table 2. Genomic alterations and Candidate MSI target
genes frameshift mutations in MSI samples.
Case
MSI
status
Genomic
subtype
Copy number
changes
Altered MSI
Target Genes
Pediatric
2452 MSI-H Stable 5q31+, 21q212 MSH6 (C)9
2458 MSI-L Stable None -
4816 MSI-L NA NA -
2444 MSI-L Aneuploid 1q+, 9q+ MRE11 (T)11/12
2457 MSI-L Aneuploid 4q2, 5q2,7p12+,
9p212, 13q2, 19+
-
2470 MSI-L Aneuploid 5q2, 10q2, 14q2,
15q2, 19+, 20p2,
Xp2
-
3952 MSI-L Aneuploid 1p2, 6p2, 12q2
13q2, 192, 22q2
-
3954 MSI-L Rearranged 1p2, 1q+, 2q+, 3q2,
4p+, 4q+, 4q2, 5q2,
6p2, 6q+, 7+, 8p+,
8q2, 11p2, 11q+,
12q2, 13q2, 182,
19q2
-
3962 MSI-L Stable None -
3967 MSI-L Stable None -
3969 MSI-L NA NA DNAPKcs (A)9/10
4820 MSI-L NA NA -
4823 MSI-L NA NA -
4839 MSI-L NA NA MRE11 (T)11/12
Adult
3248 MSI-L NA NA MRE11 (T)11/12
3283 MSI-L NA NA -
3415 MSI-L NA NA -
3416 MSI-L NA NA -
3465 MSI-L NA NA -
Abbreviations: MSI-H, microsatellite instability-High; MSI-L, microsatellite
instability-Low; NA, not available.
doi:10.1371/journal.pone.0020588.t002
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MSI is a molecular feature resulting mainly from inactivating
alterations of the MMR system [19]. We studied MMR inactivation
by immunohistochemistry on the 11 MSI tumors and observed that
MLH1 expression was absent or reduced in 10 samples, 5 of which
also presented reduced PMS2 and/or MSH2 expression. Consid-
ering the high percentage of pediatric HGG lacking MLH1
Figure 3. Target gene screening in MSI pediatric HGG. Electropherogram traces, direct sequencing, and immunohistochemistry for MSI target
genes presenting frameshift mutations in pediatric HGG (DNA alterations indicated with arrows). (A) Case RMH2452 (MSI-H) presenting a
homozygous insertion of one bp in the MSH6 poly(C)8 tract and loss of protein expression. (B) RMH3969 (MSI-L) presenting a heterozygous deletion
of one bp in the DNAPKcs poly(A)10 tract, and retention of protein expression. (C) RMH2444 (MSI-L) presenting a heterozygous insertion of one bp in
the MRE11 poly(T)11 tract and retention of protein expression.
doi:10.1371/journal.pone.0020588.g003
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expression, molecular deficiencies in this gene appear to be the
origin of the MSI phenotype in most of the cases, although we did
not observe point mutations or hypermethylation in these samples.
MSH6 expression was absent in a single sample that also
presented a homozygous insertion of a single nucleotide in
the poly(C)8 track of MSH6, which is a target of MSI. This
Figure 4. MRE11 poly(T)11/12 sequence variant has no apparent functional consequence on DNA damage detection and repair. (A)
Electropherograms and sequencing traces of the MRE11 poly(T)11 tract in leukemia/lymphoma cells: Daudi (heterozygous insertion of one bp,
poly(T)11/12); Jurkat (heterozygous deletion of one bp, poly(T)10/11); and Raji (wild-type, poly(T)11). (B) MRE11 expression in Daudi, Jurkat and Raji
cells. qRT-PCR was used to calculate the ratio of MRE11 expression (amplification of exons 2 to 4) relative to the GAPDH control, independently of the
presence of the aberrant transcript observed in Jurkat. PCR products were loaded on the gel at saturation of the reaction, being not quantitative.
MRE11 protein levels were assessed by Western blot, and were considerably lower in Jurkat. (C) ATM-pS1981 levels were assessed by Western blot in
Daudi, Jurkat and Raji after 1.5 Gy irradiation of cells and 1 h, 4 h or 24 h recovery. There was an increase of ATM phosphorylation 1 h after irradiation
in Daudi and Raji cells that decreased at the later time points. Jurkat showed no ATM phosphorylation after exposure to irradiation. (D) DNA repair
foci was observed by immunofluorescence after 1.5 Gy IR followed by 1 h and 4 h recovery. Irradiation resulted in the formation of both MRE11 and
53BP1 foci in Daudi and Raji cells, whereas Jurkat failed to form MRE11 foci. Nuclei were counterstained with DAPI. Merged figure presents co-
localization of MRE11 and 53BP1 foci visualized in yellow.
doi:10.1371/journal.pone.0020588.g004
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is the first report of this mutation in brain tumors. MSH6
poly(C)9 leads to a truncated protein and is probably the
cause of the total absence of protein assessed by immuno-
histochemistry. MSH6 mutations in the poly(C)8 microsatel-
lite are thought to arise due to germline mutations of the
MMR genes, making of MSH6 a target for somatic
mutations in the presence of MMR germline mutations
[35]. These germline mutations usually occur in the context
of familial tumors and accordingly this patient had a clinical
history consistent with a MMR deficiency syndrome such as
Turcot, in which Type A MSI has been reported in affected
children with glioblastoma [44]. Recently, MSH6 mutations
have been demonstrated to arise in gliomas as a consequence
of treatment with temozolomide, and have been implicated
in drug resistance and the presence of a hypermutated
phenotype [4,45]. Apart from the sample RMH2458, which
did not harbor any MSH6 mutation, the tumors analyzed in
this study, including the MSH6 mutated RMH2452, were
primary tumors, and have not been previously exposed to
radio or chemotherapy treatment. Therefore MSH6 findings
are not related with a previous exposure to temozolomide.
A major consequence of MSI is the accumulation of additional
mutations in key oncogenic target genes. To our knowledge, only
five known MSI target genes have been screened, with mutations
reported in a single case each of IGFIIR [7] and PTEN [9], and of
TGFbRII in 71% cases [14], although this latter observation was
not seen elsewhere [7,9]. We investigated the mutational status of
18 classical target genes in MSI HGG and, apart from MSH6,
found alterations only in two other target genes, DNAPKcs and
MRE11 which are involved in DNA DSB repair. The DNAPKcs
poly(A)9/10 sequence variant has been described in samples of
gastric and endometrial tumors [46,47], but has not been
previously reported in gliomas. In subclones of the CRC cell line
HCT-8 it failed to confer additional deficiency to DNA DSB
repair compared to the parental line [48], and we found no
alterations in protein expression in the MSI glioma sample
presenting this mutation. MRE11 poly(T)11/12 has previously
been reported in a single case of MSI CRC [49], a single case of
MSI medulloblastoma [21], and in the Daudi lymphoma cells
[26]. Our findings here demonstrate that it appears to be an
undocumented polymorphism with no functional consequences on
DNA damage detection and repair. Thus it seems that the classical
target genes for MSI in other tumor types are not frequently
mutated in gliomas, and the field would benefit from a
bioinformatic approach focusing on specific repeat sequences in
coding regions for identifying novel, possibly glioma-specific MSI
target genes as has been carried out in other tumor types [50].
The presence of MSI in pediatric HGG may have important
translational implications. Specifically, in CRC, MSI-positive
patients appear to show a differential response to 5-fluorouracil
alone [51] as well as adjuvant therapy with irinotecan,
fluorouracil, and leucovorin [52]. Furthermore, the majority of
MSI-positive tumor cell lines of different tissue origins (endome-
trial, ovarian, prostate, and colorectal carcinomas) appear
hypersensitive to drugs that produce DNA DSBs such as
bleomycin [48]. Given the considerable impact of abrogated
DNA repair capacity on gliomagenesis, identification of even a
subset of cases with a differential response to existing chemother-
apeutics would be of immense clinical benefit in these extraordi-
narily treatment refractory tumors.
In conclusion, we identified a subset of glioma patients
presenting MSI with molecular alterations distinctive of this
phenotype suggesting an association of MSI with the development
of gliomas.
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